Everolimus in Treating Patients With Recurrent Low-Grade Glioma

Model scores of the 29,894 trials active now.

Model score 35% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-11-13. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patients mustmrihearttumorstable
  Phrases that lowered it: trialvaccinestopicaldaysinfluenza
• Phase: 2 (raises risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Responsible party: sponsor investigator (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Has a data monitoring committee: not given (lowers risk) · Design
• Sponsor's past termination rate: no earlier finished trials (raises risk) · Sponsor's track record
• Disease area, neurology: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Drug's FAERS reports marked serious: 96.8% (raises risk) · Drug's FDA history
• Drug's FAERS reports with a death: 16.1% (lowers risk) · Drug's FDA history
• Sponsor's past trials: 0 (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Number of arms: 1 (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas NCT00782626 · started 2009 · scored riskier than 99% of active trials completed
• Everolimus With and Without Temozolomide in Adult Low Grade Glioma NCT02023905 · started 2014 · scored riskier than 99% of active trials terminated
• A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases NCT01305941 · started 2011 · scored riskier than 98% of active trials completed
• Everolimus and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastasis From Non-Small Cell Lung Cancer NCT00892801 · started 2009 · scored riskier than 83% of active trials terminated
• PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children NCT01734512 · started 2012 · scored riskier than 56% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.